TY - JOUR
T1 - Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
AU - Bonam, Srinivasa Reddy
AU - Kaveri, Srini V.
AU - Sakuntabhai, Anavaj
AU - Gilardin, Laurent
AU - Bayry, Jagadeesh
N1 - Funding Information:
The majority of the articles referred to in this manuscript are unpublished and have not yet undergone the peer review process. They were obtained from the various preprint servers. We thank three anonymous reviewers for their suggestions. This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), France; Centre National de la Recherche Scientifique (CNRS), France; Sorbonne Université, France; Université de Paris, France; and Institut Pasteur, France. J.B. also acknowledges the support of Agence Nationale de la Recherche (ANR-19-CE17-0021(BASIN)), France and the COVID emergency fund from Université de Paris. Article Conception, J.B.; Literature Survey and Writing, S.R.B. L.G. and J.B.; Editing and Reviewing, S.V.K. and A.S.; Final Approval, all the authors. The authors declare no competing interests.
Funding Information:
The majority of the articles referred to in this manuscript are unpublished and have not yet undergone the peer review process. They were obtained from the various preprint servers. We thank three anonymous reviewers for their suggestions. This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), France; Centre National de la Recherche Scientifique (CNRS) , France; Sorbonne Université , France; Université de Paris, France; and Institut Pasteur , France. J.B. also acknowledges the support of Agence Nationale de la Recherche ( ANR-19-CE17-0021(BASIN) ), France and the COVID emergency fund from Université de Paris.
Publisher Copyright:
© 2020 The Author(s)
PY - 2020/5/19
Y1 - 2020/5/19
N2 - Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has infected millions, with more than 275,000 fatal cases as of May 8, 2020. Currently, there are no specific COVID-19 therapies. Most patients depend on mechanical ventilation. Current COVID-19 data clearly highlight that cytokine storm and activated immune cell migration to the lungs characterize the early immune response to COVID-19 that causes severe lung damage and development of acute respiratory distress syndrome. In view of uncertainty associated with immunosuppressive treatments, such as corticosteroids and their possible secondary effects, including risks of secondary infections, we suggest immunotherapies as an adjunct therapy in severe COVID-19 cases. Such immunotherapies based on inflammatory cytokine neutralization, immunomodulation, and passive viral neutralization not only reduce inflammation, inflammation-associated lung damage, or viral load but could also prevent intensive care unit hospitalization and dependency on mechanical ventilation, both of which are limited resources.
AB - Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has infected millions, with more than 275,000 fatal cases as of May 8, 2020. Currently, there are no specific COVID-19 therapies. Most patients depend on mechanical ventilation. Current COVID-19 data clearly highlight that cytokine storm and activated immune cell migration to the lungs characterize the early immune response to COVID-19 that causes severe lung damage and development of acute respiratory distress syndrome. In view of uncertainty associated with immunosuppressive treatments, such as corticosteroids and their possible secondary effects, including risks of secondary infections, we suggest immunotherapies as an adjunct therapy in severe COVID-19 cases. Such immunotherapies based on inflammatory cytokine neutralization, immunomodulation, and passive viral neutralization not only reduce inflammation, inflammation-associated lung damage, or viral load but could also prevent intensive care unit hospitalization and dependency on mechanical ventilation, both of which are limited resources.
KW - COVID-19
KW - IVIG
KW - SARS-CoV-2
KW - convalescent plasma
KW - cytokine storm syndrome
KW - cytokines
KW - hyperimmune globulin
KW - immunotherapy
KW - inflammation
KW - monoclonal antibody
KW - passive immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85087572589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087572589&partnerID=8YFLogxK
U2 - 10.1016/j.xcrm.2020.100016
DO - 10.1016/j.xcrm.2020.100016
M3 - Review article
C2 - 32562483
AN - SCOPUS:85087572589
SN - 2666-3791
VL - 1
JO - Cell Reports Medicine
JF - Cell Reports Medicine
IS - 2
M1 - 100016
ER -